FFL
CRSP icon

Financial Freedom LLC’s CRISPR Therapeutics CRSP Stock Holding History

Financial Freedom LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.76K Hold
100
– – ﹤0.01% 362
2025
Q4 		$5.24K Hold
100
– – ﹤0.01% 295
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 300
2025
Q2 		$4.86K Hold
100
– – ﹤0.01% 309
2025
Q1 		$3.4K Hold
100
– – ﹤0.01% 325
2024
Q4 		$3.94K Hold
100
– – ﹤0.01% 320
2024
Q3 		$4.7K Hold
100
– – ﹤0.01% 311
2024
Q2 		$5.4K Hold
100
– – ﹤0.01% 315
2024
Q1 		$6.82K Hold
100
– – ﹤0.01% 298
2023
Q4 		$6.26K Hold
100
– – ﹤0.01% 302
2023
Q3 		$4.54K Buy
+100
New +$5.17K ﹤0.01% 317

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Financial Freedom LLC's CRSP Position: Q1 2026 in Review

Financial Freedom LLC held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 100 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #362.

Financial Freedom LLC first reported a position in CRSP in Q3 2023 and has held it in 11 quarters since. The position peaked at $6.82K in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Financial Freedom LLC held 100 shares of CRISPR Therapeutics worth $4.76K as of Q1 2026.
  • Financial Freedom LLC left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Financial Freedom LLC's portfolio in Q1 2026, its #362 holding.
  • Financial Freedom LLC first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Financial Freedom LLC's CRISPR Therapeutics position peaked at $6.82K in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Financial Freedom LLC's 13F filing for Q1 2026, filed 30 Apr 2026.